biostudies-literatureUnknown10(49)Ramadan SKHerein, we report an eco-friendly synthesis of a new series of quinazolinone-based derivatives as potential PARP-1 inhibitors. The 4-quinazolinone scaffold was utilized as a bioisostere to the phthalazinone core of the reference compound Olaparib. Most of the synthesized compounds displayed appreciable inhibitory activity against PARP-1. Compound 12c showed inhibitory activity at IC₅₀ = 30.38 nM comparable to Olaparib, which has IC₅₀ = 27.89 nM. Cell cycle analysis was performed for compounds 12a and 12c, and both exhibited cell growth arrest at G2/M phase in the MCF-7 cell line. In addition, both compounds increased the programmed apoptosis compared to the control. Furthermore, molecular docking of the final compounds into the PARP-1 active site was executed to explore their probable binding modes. Also, a computational QSAR and <i>in silico</i> ADMET study was performed. The results of this study revealed that some of the newly synthesized compounds could serve as a new framework to discover new PARP-1 inhibitors with anti-cancer activity.RSC advances29475-29492https://www.ebi.ac.uk/biostudies/studies/S-EPMC9055986biostudies-literatureDesign, synthesis and <i>in silico</i> studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors.PMC9055986Elrazaz EZEl-Naggar AMRamadan SKAbouzid KAMfalseDesign, synthesis and <i>in silico</i> studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors.Herein, we report an eco-friendly synthesis of a new series of quinazolinone-based derivatives as potential PARP-1 inhibitors. The 4-quinazolinone scaffold was utilized as a bioisostere to the phthalazinone core of the reference compound Olaparib. Most of the synthesized compounds displayed appreciable inhibitory activity against PARP-1. Compound 12c showed inhibitory activity at IC₅₀ = 30.38 nM comparable to Olaparib, which has IC₅₀ = 27.89 nM. Cell cycle analysis was performed for compounds 12a and 12c, and both exhibited cell growth arrest at G2/M phase in the MCF-7 cell line. In addition, both compounds increased the programmed apoptosis compared to the control. Furthermore, molecular docking of the final compounds into the PARP-1 active site was executed to explore their probable binding modes. Also, a computational QSAR and <i>in silico</i> ADMET study was performed. The results of this study revealed that some of the newly synthesized compounds could serve as a new framework to discover new PARP-1 inhibitors with anti-cancer activity.2020-01-01T00:00:00Z2020 Aug2026-05-30T20:53:36.512Z2025-04-04T10:02:18.454ZS-EPMC90559863552110410.1039/d0ra05943a